Opinion|Videos|January 26, 2026
Other Key Updates and Ongoing Research in Non-Advanced Systemic Mastocytosis From ASH 2025
Author(s)Lindsay Rein, MD, Frederick Lansigan, MD
Lindsay Rein, MD, and Frederick Lansigan, MD, detail other key data from ASH 2025 for non-advanced systemic mastocytosis and ongoing research to watch in the space.
Advertisement
Episodes in this series
Lindsay Rein, MD, and Frederick Lansigan, MD, highlight other notable data in non-advanced systemic mastocytosis presented at the 2025 ASH Annual Meeting and Exposition. They discuss emerging therapies, ongoing clinical trials, and areas of active investigation aimed at improving symptom control and quality of life. Rein and Lansigan conclude by emphasizing future research directions and closing the program with final reflections on progress in the field.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.
Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.
Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.
Ofirnoflast produced hematologic improvement in two-thirds of patients with ESA-refractory lower-risk MDS.
Mayo Clinic researchers identified a potential new approach to treating glioblastoma to improve the effectiveness of existing chemotherapy.
In the phase 2 RESTORE-PV trial, DISC-3405 cut phlebotomy events and maintained hematocrit below 45% in patients with polycythemia vera.
Selcodebart improved hemoglobin levels and transfusion independence across 3 anemia cohorts in myelofibrosis, regardless of concomitant JAK inhibitor use.
Advertisement
Advertisement
Trending on OncLive
1
Revumenib Plus Chemo Yields High Response and MRD-Negativity Rates in Newly Diagnosed NPM1+ or KMT2A+ AML
2
Ofirnoflast Elicits Durable Transfusion Independence, Hematologic Improvement in Lower-Risk MDS
3
ACTIVE Regimen Elicits High Response Rates in R/R NPM1-Mutated AML
4
DISC-3405 Reduces Phlebotomy Events and Controls Hematocrit in Polycythemia Vera
5